Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07710118

500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection

This is a study to compare the treatment effect of different doses of ceftriaxone for gonorrhea.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location status: Recruiting

Location contact

Tzong-Yow Wu, M.D.

CONTACT

[email protected]

886+933594074

About this study

This is a noninferiority randomized controlled trial to compare the treatment effect of 500-mg to 1000-mg of ceftriaxone for uncomplicated gonorrhea infection in men.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older man, and
  • having oropharyngeal, anorectal or urogenital N. gonorrhoeae infection confirmed by culture or a positive NAAT

Exclusion criteria

  • Suspicion of a complicated N. gonorrhoeae infection. Complicated N. gonorrhoeae infection is defined as the presence of epididymitis, arthritis, bacteremia, conjunctivitis, or disseminated gonococcal infection.
  • Use of systemic cephalosporins, doxycycline, or azithromycin at the screening visit or within 30 days prior to the enrollment visit is prohibited. Participants who require immediate antibiotic treatment at the screening visit, based on clinician judgment or shared decision-making with the participant, without awaiting PCR or culture confirmation, will be excluded from the study. Use of doxycycline for post-exposure prophylaxis (Doxy-PEP) is permitted.
  • A NAAT test positive for C. trachomatis or M. genitalium at the screening visit.
  • A history of allergy or intolerance to ceftriaxone, penicillins, or lidocaine, in alignment with the contraindications listed in the Sintrix (ceftriaxone) injection package insert. Allergy or intolerance is defined as the occurrence of adverse symptoms following antibiotic administration, including but not limited to skin rash, pruritus, dyspnea, angioedema, anaphylaxis, dizziness, nausea, vomiting, headache, or diarrhea. Laboratory abnormalities include cytopenias, eosinophilia, and elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or creatinine. Penicillins include natural penicillins (e.g., penicillin G), aminopenicillins (e.g., amoxicillin, ampicillin), penicillinase-resistant penicillins (e.g., oxacillin, dicloxacillin), extended-spectrum penicillins (e.g., piperacillin), and other agents classified within the penicillin class.

Treatment and study plan

ceftriaxone 500-mg

Drug

single-dose ceftriaxone 500-mg intramuscular injection, dissolved in 2 mL of 1% lidocaine hydrochloride solution

ceftriaxone 1000-mg

Drug

single-dose ceftriaxone 1000-mg intramuscular injection, dissolved in 3.5 mL of 1% lidocaine hydrochloride solution

Primary outcomes

  1. Treatment response of UGI

    Time frame: From enrollment to 14 days after treatment

    The proportion of participants with successful treatment of UGI, defined as a NAAT-negative and, if applicable, a culture-negative result of the primary anatomic sites of infection 7-14 days after treatment; a culture-negative result is required only if N. gonorrhoeae culture was positive at the screening visit.

Secondary outcomes

  1. Symptom duration

    Time frame: From enrollment to 14 days after treatment

    Symptom duration, including dysuria, genital discharge, sore throat, anorectal pain, rectal bleeding, and rectal discharge, in the subgroup of patients who have baseline symptoms attributable to UGIs.

  2. Treatment-related adverse events

    Time frame: From enrollment to 14 days after treatment

    Treatment-related adverse events until 14 days after treatment.

  3. MIC of ceftriaxone of isolates

    Time frame: From enrollment to 14 days after treatment

    MIC of ceftriaxone of isolates at screening and test-of-cure (TOC) visits.

  4. NG-MAST

    Time frame: From enrollment to 14 days after treatment

    NG-MAST at screening and TOC visits.

  5. Gene mutations associated with drug resistance for extended-spectrum cephalosporins

    Time frame: From enrollment to 14 days after treatment

    Gene mutations associated with drug resistance for extended-spectrum cephalosporins at screening and TOC visits.

Study contacts

Contact information is provided by the study sponsor or research team.

Tzong-Yow Wu, M.D.

CONTACT

[email protected]

886+933594074

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Collaborators

  • Far Eastern Memorial Hospital
  • National Taiwan University Hospital Hsin-Chu Branch
  • National Taiwan University Hospital, Yun-Lin Branch

Registry information

Official study title

500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection: A Noninferiority Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jul 17, 2026
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.